The identified four proteins, PON1, IGFBP3, v-kappa-3 and DDX55, can achieve the early identification of IC beneficiaries while diagnosing LA-NPC, and they could confirm whether the identified potential beneficiaries have been effectively treated after IC, and distinguish responders and non-responders. This evidence concerns the gene IGFBP3 and nasopharyngeal carcinoma.